Atea Pharmaceuticals, Inc.
$4.43
The Read: Atea Pharmaceuticals’ stock surged about 57% after Q4 2025 earnings on progress in its Hepatitis C late-stage program and Hepatitis E pipeline updates, but then plunged about 29% post-Q1 2026 earnings as investors de-risked ahead of the pivotal C-BEYOND trial readout despite no negative news.
Price
Overlays
Panel
AVIR
Hover to view data
No Data